Business Context and Reporting Period
This Form 8-K was filed by Wave Life Sciences Ltd. on July 3, 2017. The report addresses a corporate governance event regarding the departure of a director.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements.
Material Changes
The material change reported is the retirement of Masaharu Tanaka from the Board of Directors. Mr. Tanaka informed the Board on July 3, 2017, that he will not seek re-election at the upcoming 2017 Annual General Meeting. His departure follows his recent retirement from Kagoshima Development Co. Ltd. and is not related to any disagreement regarding the company's operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. Management commentary is limited to thanking Mr. Tanaka for his service since August 2014 and noting his role in helping transition the company to a public listing in 2015.
Key Facts for Investor Verification
- Masaharu Tanaka is retiring from the Board of Directors effective at the 2017 Annual General Meeting.
- The departure is voluntary and unrelated to any disputes with the company.
- Mr. Tanaka joined the board in August 2014 in connection with an initial investment by Kagoshima Shinsangyo Sousei Investment Limited Partnership.
- The report was signed by Paul B. Bolno, M.D., President and Chief Executive Officer, on July 6, 2017.